A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
about
Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC EfficacyChallenges and advances in the assessment of the disposition of antibody-drug conjugatesField Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug ConjugatesApplication of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Integration of bioanalytical measurements using PK-PD modeling and simulation: implications for antibody-drug conjugate development.Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates.Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling.Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays.Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays.
P2860
Q27303016-B62C4A09-735A-456D-99FD-B35BE1415EDCQ28085074-66648C92-A355-4E0B-AA62-6EAA9B791CB1Q37066113-51BEFC77-931D-422B-B52D-EC79700D20C6Q37327321-885D154F-8523-48B4-A419-442EB10B66B3Q37585671-349291F3-4CB5-419D-A690-DE36B7A66EDDQ38275051-9389836A-80F4-40D0-AE8A-086BCCC9CBC4Q38350045-70153393-4EE8-49F3-9D44-87692DF9FCE7Q38453769-F38DB49A-CFB6-4322-8178-62D8D3FA975AQ38489049-CE6E9C45-298C-4B90-A5E6-537ABD2FE01FQ38557522-146BAF55-7A50-4437-9D77-5EB745D2277DQ38624597-732DB2DC-7269-43B8-BFC1-E2FD5F5EAAEFQ38764062-25CB71FC-AC01-4049-B00A-774952740C58Q38765188-BE173CF8-F4B9-4D1A-A1A9-B25254028453Q38856969-1436452A-E893-47FD-A51D-1371E2455BE3Q39085203-599218F3-C31A-4818-A89B-5B92A59A71B7Q39174329-3D6F3104-4461-4393-9DA3-B5F785BAC13FQ40677785-D6182D40-1242-4DEC-932E-00D82F6D7FA9Q46535634-1BAA08ED-9393-4A8A-B759-D45DD3B83430
P2860
A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@ast
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@en
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@nl
type
label
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@ast
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@en
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@nl
prefLabel
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@ast
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@en
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@nl
P2093
P2860
P1433
P1476
A mechanistic pharmacokinetic ...... t of metastatic breast cancer.
@en
P2093
Ben-Quan Shen
Brendan Bender
Douglas D Leipold
Jay Tibbitts
Lena E Friberg
P2860
P2888
P304
P356
10.1208/S12248-014-9618-3
P407
P577
2014-06-11T00:00:00Z
P6179
1037300585